NCNoah Craft

Noah Craft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noah Craft has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune Defense Protein IDP® Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study

    by Azure D. Grant, Cypress S. Prideaux, Miguel Rosales, Lisa Capano-Wehrle, Jordan Moos, Nicole Mkrtytchian, Veronica Luna, Marie Crisel E. Krupa, Noah Craft

    Background: Upper respiratory infections are common and carry a greater burden in older adults. IDP ® (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP ® report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP ® supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods: This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP® /day, and advanced dose of 200mg IDP® /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results: N=255 participants (n=88 Placebo, n=85 50 mg IDP®, n=82 200 mg IDP®) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP® and 200 mg IDP® groups compared to Placebo (KW for Area Under the Curve p 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions: Sixteen weeks of daily IDP® supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP® appears safe and tolerable. Trial Registration: The trial was reviewed and approved by BeyondBound IRB: BB2511NC-152, and registered at clinicaltrials.gov ( NCT07431840 )

  • Open Access

    Lactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study

    by A.D. Grant, M.C.B. Erfe, C.J. Delebecque, D. Keller, N.P. Zimmerman, P.L. Oliver, B. Youssef, J. Moos, V. Luna, N. Craft

    The major inhibitory neurotransmitter gamma-aminobutyric acid or GABA plays a pivotal role in mood and sleep. GABA exerts sedative and anxiolytic effects both within the central nervous system and through the gut-brain axis, which has generated interest in the potential for gut GABA to modulate mood and sleep. Several bacterial strains can produce GABA, yet their real-world impacts are poorly understood. We investigated the impact of 2 doses of the strain Lactiplantibacillus plantarum Lp815 on anxiety, sleep, mood, quality of life, cognition, heart rate variability and adverse events in adults with mild to moderate anxiety over a 6-week period. The trial was structured as a double-blinded, randomised, placebo-controlled trial with optional open label extension. Participants were blindly assigned to receive either a placebo, 1 billion colony-forming units (CFU), or 5 billion CFU of the oral capsule per day. Participants completed biweekly anxiety, insomnia and cognition measures, daily mood, sleep, and quality of life surveys, and collected wearable heart rate variability. 83 individuals were evaluated, aged 39 ± 13 years, 63% female and 64% Caucasian. Participants receiving 5 billion CFU exhibited significantly lower anxiety (GAD-7) scores at weeks 4 and 6 compared to placebo (Kruskal-Wallis ). This result was clinically meaningful, with 68% of participants in the 5 billion CFU cohort exhibiting improvement by more than one category in their GAD-7 scores at week 6, compared to 37% in the 1 billion CFU group and 26% in the placebo group (e.g. from moderate to no anxiety) (Fisher’s exact test for 5 billion CFU vs Placebo). No serious adverse events occurred. A daily capsule containing 5 billion CFU Lp815 significantly reduced anxiety in a diverse cohort of adults at 4 and 6 weeks following daily consumption. GABA-producing probiotics may offer a safe option for anxiety reduction in people with mild to moderate anxiety. Trial Registration. The trial was IRB approved and registered with ClinicalTrials.gov (NCT06466603).